Clinical Trial Corner

Approximately 100,000 patients with stage 1 to stage 3 solid tumors will be enrolled onto the trial across 25 sites, according to the manufacturer of the test aimed at detecting cancer recurrence.

The early-stage trial, according to the investigational drug’s manufacturer, Adagene, is expected to take place across multiple sites in the United States and Asia Pacific.

Four sites across the United States are enrolling patients with locally advanced or metastatic pancreatic cancer to see if a novel drug combined with standard-of-care chemotherapy bests chemotherapy alone in survival outcomes and responses to treatment.

The rare cancer, known as adenoid cystic carcinoma, is diagnosed in fewer than 1,500 people in the United States each year and is often found in the salivary glands, a part of the body associated with helping a person swallow and digest food.

The study authors plan to enroll 32 patients with advanced pancreatic cancer into the trial to assess the efficacy and safety of an experimental treatment combination.

The goal of the phase 2 trial is to study the safety and efficacy of ASP-1929, a photoimmunotherapy with fluorescence imaging, in patients with head and neck or skin cancer.

A trial to examine BMF-219 in patients with relapsed or refractory acute leukemias has begun recruiting patients across multiple U.S. states.

A phase 3 trial evaluating the safety and efficacy of the BTK inhibitor LOXO-305 in patients with previously treated mantle cell lymphoma is now open to patients across more than a dozen states.

A phase 2b clinical trial evaluating the efficacy and safety of an immunotherapy drug for patients with brain cancer has opened at Roswell Park Comprehensive Cancer Center in Buffalo, New York, with additional plans to be carried out at more than a dozen sites.

A phase 1/2a clinical trial examining the effects of a treatment called LAVA-1207 for patients with metastatic prostate cancer has now begun.

A clinical trial to evaluate Descartes-25, a novel allogeneic RNA cell therapy, for multiple myeloma has officially treated its first patient and is now recruiting in certain locations.

A new study to evaluate the accuracy of a blood test for detecting lung cancer in high-risk adults has enrolled its first participant with plans to enroll thousands more.

Enrollment has begun for a trial evaluating a vaccine as first-line maintenance treatment for metastatic, microsatellite-stable colorectal cancer.

A phase 3 trial has begun to examine entospletinib, a selective inhibitor, as a treatment for patients with newly diagnosed NPM1-mutated acute myeloid leukemia.

A phase 2 trial was recently launched to examine the safety and efficacy of oral inhibitor VK-2019 in patients with advanced Epstein-Barr Virus-positive nasopharyngeal carcinoma, a rare type of head and neck cancer, and lymphoma.

The phase 3 COMPOSE trial will look at the efficacy of using 177lu-edotreotide — a novel radiopharmaceutical that is designed to limit radiation exposure to normal tissue — in patients with later stage neuroendocrine tumors.

There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.

City of Hope has opened its first-in-human clinical trial for an investigational therapy in patients with advanced breast cancer.

Investigators plan to analyze the safety and efficacy of a novel cancer therapy for the treatment of patients with RAF-altered solid tumors.

The first patient was randomized in the phase 2 trial examining Tedopi and Opdivo for non-small cell lung cancer.

Part B of the DIONE-01 study will look at whether IOA-244 increases anti-tumor responses in expansion groups of patients.

A phase 2 trial of aspacytarabine (BST-236) was initiated in patients with AML and MDS.

The TRANSCEND CLL 004 trial is currently enrolling patients to determine the efficacy of a CAR-T cell therapy.

The first patient with bladder cancer was dosed in a phase 1/2 trial examining responses to an investigational immunotherapy.

The first patient has been enrolled in the APOLLO 613 Phase 1/2 clinical trial for CPI-613.

A phase 1 trial of ONO-4685 was initiated for the evaluation of the antibody in patients with relapsed or refractory t-cell lymphoma.

The Food and Drug Administration gave clearance to Bold Therapeutics for a phase 1b/2a trial examining treatments for advanced GI cancers.

The first patients were dosed in a phase 2 trial for a topical gel to treat lesions in patients with colorectal cancer receiving EGFR inhibitor therapy.